Each year we unleash the creative beast in the DevicePharm team in a no-holds-barred Gingerbread House contest. Art directors and accountants, writers and editors, animators and account executives; everybody gets to build the gingerbread house of their dreams. And, as the winning categories indicate, some of those dreams are sweet and others may be best classified as nightmares.
OCTANe launched the 10th annual Medical Device & Investor Forum on November 2, 2015 at the Hotel Irvine by introducing an expanded vision for Orange County’s technology industry accelerator. The presentation included an introduction of the expanded brand scope and new branding elements by DevicePharm CEO & Chief Strategy Officer, Clay Wilemon.
Millions of Americans have considered weight loss surgery but made the decision that although they wanted significant weight loss, surgery was too big of a step for them. Now, with the U.S. FDA’s approval of the ReShape™ Integrated Dual Balloon System, a non-surgical weight loss procedure is available in the United States. It is called theReShape Procedure and is indicated for people with a BMI of 30 to 40.
The mindset a few years ago for website development was to consider how a digital property was going to look on a mobile device. As responsive design became a reality, the logic shifted to one focused on providing a quality mobile user experience . Now, with mobile usage far surpassing computer usage for initial searches, we have to have a mobile optimized mindset as we create content for healthcare professionals.
What if you could focus your marketing plans and messaging only on the people who were actually going to buy your product or service?” This was the question posed by Clay Wilemon, DevicePharm CEO & Chief Strategy Officer, to an enthusiastic audience in San Diego during the September Device Alliance meeting.
The reality is that using predictive analytics in market research is providing a more precise way of targeting, messaging, and selling to the customers who are actually going to buy your products.
In August of 2015, the Freudenberg Group announced the formation of Freudenberg Medical. The new entity combines the resources and expertise of minimally invasive medical device specialty component, product development, and manufacturing leaders Helix Medical and MedVenture Technology under the Freudenberg Medical umbrella. By combining these two teams with the global resources of Freudenberg, medical device and pharmaceutical companies will have access to an exceptional breadth of resources in a single source relationship supported by 40,000 associates in 60 nations. The company also has manufacturing facilities in five countries including the United States, Costa Rica, Germany, Ireland, and China.
Bausch + Lomb is an iconic brand with both consumers and eye care professionals. The company launched their new Bausch + Lomb Surgical corporate campaign at the 2015 ASCRS meeting in San Diego. This campaign reflects an expanded portfolio of differentiated technologies and services for ophthalmic surgeons.
Medical device and pharmaceutical companies spend billions of dollars each year trying to reach, educate, and influence physicians and surgeons. In the past, it was easy – just send a sales rep to the office, take lunch, and tell the physicians and staff about your product.
The OCTANe Ophthalmology Summit is a unique convocation of ophthalmology executives, researchers, entrepreneurs, investors, physicians, and surgeons. Held each year in Orange County, CA, the global ophthalmic industry hub, this event provides an important opportunity for innovators to gather and share ideas about the growth and future of this important medical industry segment.
A recent Medical Marketing & Media article indicated that 55% of pharmaceutical companies are either partially or strongly dissatisfied with their multi-channel marketing efforts. The article went on to quote that, “When integrated across an organization and executed properly, multi-channel campaigns can boost top-line growth by more than 10% and reduce overall promotional costs by 10% to 25%.” So where is the disconnect between multi-channel marketing effectiveness and multi-channel marketing dissatisfaction?